Maxcyte, Inc.

MXCT chart

Maxcyte, Inc. news

• Genomics for CRISPR: An introduction to genomic safety assessment

  News-Medical · Oct 27, 12:33 PM EDT

• High-throughput electroporation for cell therapy discovery

  News-Medical · Oct 27, 10:34 AM EDT

• How dual checkpoint knockout strengthens engineered TIL therapy

  News-Medical · Oct 27, 10:34 AM EDT

• Risk assessment of PCSK9 guide RNAs

  News-Medical · Oct 27, 10:34 AM EDT

• MaxCyte, Inc. Estimates – NASDAQ:MXCT

  TradingView · Oct 23, 10:45 AM EDT

• CMN Webinar - History of Genome Safety & Regulatory Requirements

  CRISPR Medicine News · Oct 22, 2:00 AM EDT

• MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

  Yahoo Finance · Oct 14, 8:05 AM EDT

• Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?

  Yahoo Finance · Oct 6, 4:07 AM EDT

• MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

  Yahoo Finance · Sep 23, 8:05 AM EDT

• MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Yahoo Finance · Sep 11, 4:30 PM EDT

• MaxCyte (MXCT) Q2 2026 Earnings Call Transcript

  fool.com · Aug 19, 7:01 PM EDT

• MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

  Yahoo Finance · Aug 19, 8:05 AM EDT

Maxcyte, Inc. key financials

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 8-KFORM 8-K2026-10-14
• 10-Q10-Q2026-08-13
• 8-K8-K2026-08-12
• 8-K8-K2026-06-17
• 8-K8-K2026-06-16
• 10-Q10-Q2026-05-13
• 8-K8-K2026-05-12
• DEF 14ADEF 14A2026-04-29
• 8-K8-K2026-03-27
• 10-K10-K2026-03-25
• 8-K8-K2026-03-24
• 8-K8-K2026-03-20

About Maxcyte, Inc.

Ticker

MXCT (Nasdaq)

Industry

Services-Commercial Physical & Biological Research

Headquarters

Rockville, MD

Incorporated in

DE

Fiscal year end

December 31

SEC CIK

1287098

Former names

MAXCYTE INC

Frequently asked questions